Article Text
Statistics from Altmetric.com
- CABG, coronary artery bypass graft
- ISR, in-stent restenosis
- MACE, major adverse cardiac events
- PCI, percutaneous coronary intervention
- SES, sirolimus eluting stent
- VBT, vascular brachytherapy
- percutaneous coronary intervention
- angioplasty
- sirolimus eluting stent
- in-stent restenosis
- vascular brachytherapy
Since they were first introduced 17 years ago,1 bare metallic stents have improved the outcome of angioplasty.2 However, in-stent restenosis (ISR) remains a major limitation with an incidence of additional revascularisation of 17–21 %. Among the several approaches proposed to address this problem, vascular brachytherapy (VBT) has given the best results, with an incidence of major cardiac events at nine months from 18–28 %.3 The preliminary results reported with the use of sirolimus eluting stents (SES) in de novo lesions were encouraging.4 We report our results with both techniques in patients with ISR.
METHODS
Between April 2001 and mid April 2002 all patients with ISR were treated with VBT, and from mid April to November 2002 they received one or several SES within the previous stent. The data from these patients were included in a prospective registry. All patients were pre-treated with aspirin 100 mg/day. Intravenous heparin was given initially and a 300 …